慢性丙型肝炎的管理：共识指南
Management of chronic hepatitis C: consensus guidelines.
作者信息
Sherman Morris, Shafran Stephen, Burak Kelly, Doucette Karen, Wong Winnie, Girgrah Nigel, Yoshida Eric, Renner Eberhard, Wong Philip, Deschênes Marc
机构信息
Department of Medicine, University of Toronto, Toronto General Hospital, Toronto, Ontario, Canada.
出版信息
Can J Gastroenterol. 2007 Jun;21 Suppl C(Suppl C):25C-34C.
Abstract
Since the last consensus conference on the management of chronic viral hepatitis, a number of studies looking at modifications of the standard course of treatment have been published. These changes have been sufficiently substantive to warrant review to determine whether any changes in the recommended treatment algorithms are needed. A consensus development conference was held in January 2007, and the present document highlights the results of the presentations and discussion about these issues. It reviews the epidemiology of hepatitis C in Canada, treatment of acute hepatitis C and new algorithms in chronic hepatitis C, including retreatment of previous treatment failures. In addition, sections on management of hepatitis C in special populations have been updated. There is also a section on the use of hematopoietic growth factors to help manage patients on therapy. The document should be read in conjunction with the previous document to identify changes. Some recommendations made in the previous document remain and are not discussed here.
摘要
自上次关于慢性病毒性肝炎管理的共识会议以来，已经发表了一些关于修改标准治疗疗程的研究。这些变化相当重大，值得进行审查，以确定推荐的治疗算法是否需要任何改变。2007年1月召开了一次共识发展会议，本文件重点介绍了关于这些问题的报告和讨论结果。它回顾了加拿大丙型肝炎的流行病学、急性丙型肝炎的治疗以及慢性丙型肝炎的新算法，包括对先前治疗失败患者的再治疗。此外，关于特殊人群丙型肝炎管理的章节也已更新。还有一节关于使用造血生长因子来帮助管理接受治疗的患者。本文件应与先前的文件一并阅读，以确定其中的变化。先前文件中的一些建议仍然有效，在此不再讨论。
相似文献
1
Management of chronic hepatitis C: consensus guidelines.慢性丙型肝炎的管理：共识指南
Can J Gastroenterol. 2007 Jun;21 Suppl C(Suppl C):25C-34C.
2
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.丙型肝炎管理的最新进展：加拿大肝脏研究协会的共识指南
Can J Gastroenterol. 2012 Jun;26(6):359-75. doi: 10.1155/2012/947676.
3
Management of chronic hepatitis B: consensus guidelines.慢性乙型肝炎的管理：共识指南
Can J Gastroenterol. 2007 Jun;21 Suppl C(Suppl C):5C-24C.
4
APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.亚太肝脏研究学会关于丙型肝炎预防、流行病学及实验室检测的共识声明与建议
Hepatol Int. 2016 Sep;10(5):681-701. doi: 10.1007/s12072-016-9736-3. Epub 2016 May 26.
5
[Highlights of the guidelines of prevention and treatment for hepatitis C (2019 version)].[丙型肝炎防治指南（2019年版）要点]
Zhonghua Gan Zang Bing Za Zhi. 2020 Feb 20;28(2):129-132. doi: 10.3760/cma.j.issn.1007-3418.2020.02.005.
6
An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver.慢性丙型肝炎管理的最新进展：加拿大肝病研究协会 2015 年共识指南。
Can J Gastroenterol Hepatol. 2015 Jan-Feb;29(1):19-34. doi: 10.1155/2015/692408. Epub 2015 Jan 13.
7
The management of chronic viral hepatitis: a Canadian consensus conference 2004.慢性病毒性肝炎的管理：2004年加拿大共识会议
Can J Gastroenterol. 2004 Dec;18(12):715-28. doi: 10.1155/2004/201031.
8
NIH Consensus Statement on Management of Hepatitis C: 2002.美国国立卫生研究院关于丙型肝炎管理的共识声明：2002年。
NIH Consens State Sci Statements. 2002;19(3):1-46.
9
Consensus of the Brazilian Society of Infectious Diseases on the management and treatment of hepatitis C.巴西传染病学会关于丙型肝炎管理与治疗的共识
Braz J Infect Dis. 2007 Oct;11(5):446-50. doi: 10.1590/s1413-86702007000500001.
10
[Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis].[匈牙利B、C和D型病毒性肝炎诊断与治疗共识指南]
Orv Hetil. 2012 Mar 11;153(10):375-94. doi: 10.1556/OH.2012.29338.
引用本文的文献
1
Characterizing the cascade of care for hepatitis C virus infection among Status First Nations peoples in Ontario: a retrospective cohort study.描述安大略省第一民族人群丙型肝炎病毒感染的关怀级联：一项回顾性队列研究。
CMAJ. 2023 Apr 11;195(14):E499-E512. doi: 10.1503/cmaj.220717.
2
Characterizing risk behaviour and reinfection rates for successful programs to engage core transmitters in HCV elimination (C-RESPECT).确定成功项目中核心传播者参与丙型肝炎病毒消除（C-RESPECT）的风险行为和再感染率。
Can Liver J. 2021 Nov 11;4(4):346-359. doi: 10.3138/canlivj-2021-0005. eCollection 2021 Fall.
3
A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania.一项真实世界研究，比较在罗马尼亚布加勒斯特 Fundeni 临床学院的 587 例慢性丙型肝炎患者中，使用帕利瑞韦/奥比他韦/利托那韦联合或不联合利巴韦林的安全性和疗效。
Med Sci Monit. 2022 Jul 5;28:e936706. doi: 10.12659/MSM.936706.
4
Assessing State Variation in Plastic Surgeons' Risk of Hepatitis C Exposure: Revisit in Methodology.评估整形外科医生丙型肝炎暴露风险的州际差异：方法学再探讨。
Plast Reconstr Surg Glob Open. 2020 Oct 27;8(10):e3220. doi: 10.1097/GOX.0000000000003220. eCollection 2020 Oct.
5
Prevalence and genotyping pattern of hepatitis C virus among patients on maintenance hemodialysis at five centers in Pune, India.印度浦那五个中心维持性血液透析患者中丙型肝炎病毒的流行率和基因分型模式
Med J Armed Forces India. 2019 Jan;75(1):74-80. doi: 10.1016/j.mjafi.2018.08.001. Epub 2018 Nov 22.
6
Hepatitis C surveillance in Canada.加拿大的丙型肝炎监测
Can Commun Dis Rep. 2014 Dec 18;40(19):421-428. doi: 10.14745/ccdr.v40i19a01.
7
Let's Talk About B: Barriers to Hepatitis B Screening and Vaccination Among Asian and South Asian Immigrants in British Columbia.让我们谈谈 B：不列颠哥伦比亚省亚洲和南亚移民中乙型肝炎病毒筛查和疫苗接种的障碍。
J Racial Ethn Health Disparities. 2018 Dec;5(6):1337-1345. doi: 10.1007/s40615-018-0483-0. Epub 2018 Mar 19.
8
Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies.聚乙二醇干扰素α-2b联合利巴韦林在加拿大初治基因2型或3型慢性丙型肝炎患者队列中的真实世界疗效：PoWer和RediPEN研究结果
Eur J Clin Microbiol Infect Dis. 2016 Apr;35(4):597-609. doi: 10.1007/s10096-016-2576-1. Epub 2016 Feb 6.
9
Cost-effectiveness of screening for hepatitis C in Canada.加拿大丙型肝炎筛查的成本效益
CMAJ. 2015 Feb 17;187(3):E110-E121. doi: 10.1503/cmaj.140711. Epub 2015 Jan 12.
10
Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.注射吸毒者接受丙型肝炎病毒感染治疗的资格。
World J Gastroenterol. 2014 Sep 28;20(36):12722-33. doi: 10.3748/wjg.v20.i36.12722.
本文引用的文献
1
Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.将聚乙二醇干扰素和利巴韦林治疗丙型肝炎基因1型感染的慢反应者的疗程延长至72周。
Hepatology. 2007 Dec;46(6):1688-94. doi: 10.1002/hep.21919.
2
Infection rates in HIV-HCV patients treated with interferon are similar to those in HCV mono-infection and not related to neutropenia.接受干扰素治疗的HIV-HCV患者的感染率与HCV单一感染患者相似，且与中性粒细胞减少无关。
HIV Clin Trials. 2006 Sep-Oct;7(5):251-4. doi: 10.1310/hct0705-251.
3
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.疾病严重程度对慢性丙型肝炎抗病毒治疗结局的影响：来自HALT-C试验的经验教训。
Hepatology. 2006 Dec;44(6):1675-84. doi: 10.1002/hep.21440.
4
Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study.聚乙二醇干扰素α-2b与利巴韦林治疗丙型肝炎病毒合并失代偿期肝硬化患者：一项对照研究。
J Hepatol. 2007 Feb;46(2):206-12. doi: 10.1016/j.jhep.2006.08.020. Epub 2006 Oct 20.
5
Follow-up for medical care among drug users with hepatitis C.丙型肝炎吸毒者的医疗随访。
Eval Health Prof. 2006 Dec;29(4):355-66. doi: 10.1177/0163278706296003.
6
Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C.聚乙二醇化干扰素α2a（40kd）在慢性丙型肝炎儿童中的安全性、有效性及药代动力学
J Pediatr Gastroenterol Nutr. 2006 Oct;43(4):499-505. doi: 10.1097/01.mpg.0000235974.67496.e6.
7
Sustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatment.聚乙二醇化干扰素α-2b联合利巴韦林治疗对既往治疗无效的慢性丙型肝炎的持续病毒学应答
Dig Dis Sci. 2006 Nov;51(11):1956-61. doi: 10.1007/s10620-006-9192-3. Epub 2006 Sep 27.
8
Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C.老年患者在丙型肝炎抗病毒治疗期间发生血细胞减少的风险更高。
Can J Gastroenterol. 2006 Sep;20(9):589-92. doi: 10.1155/2006/357259.
9
Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.在HIV感染者的丙型肝炎病毒（HCV）治疗期间，使用齐多夫定而非基于体重的利巴韦林给药会影响贫血情况。
J Viral Hepat. 2006 Oct;13(10):683-9. doi: 10.1111/j.1365-2893.2006.00749.x.
10
Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems.感染人类免疫缺陷病毒/丙型肝炎病毒（HIV/HCV）且有酒精问题的成年患者在丙型肝炎治疗方面存在的障碍。
Alcohol Clin Exp Res. 2006 Sep;30(9):1520-6. doi: 10.1111/j.1530-0277.2006.00183.x.
Zotero 插件